Eli Lilly has filed six lawsuits against companies allegedly involved in the illegal sale of its experimental obesity drug, retatrutide. The pharmaceutical giant is intensifying its efforts to combat the burgeoning black market, calling on online platforms, payment companies, and regulators to take action against unauthorized sales. As the market is flooded with unverified versions of retatrutide, Lilly aims to protect consumers and uphold the integrity of its drug development process. The lawsuits highlight the dangers posed by counterfeit medications that are being sold despite the drug still undergoing testing for safety and efficacy.